17 reports of this reaction
1.8% of all PHENOBARBITAL SODIUM reports
#9 most reported adverse reaction
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION is the #9 most commonly reported adverse reaction for PHENOBARBITAL SODIUM, manufactured by BPI Labs LLC. There are 17 FDA adverse event reports linking PHENOBARBITAL SODIUM to DRUG INEFFECTIVE FOR UNAPPROVED INDICATION. This represents approximately 1.8% of all 956 adverse event reports for this drug.
Patients taking PHENOBARBITAL SODIUM who experience drug ineffective for unapproved indication should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION is a less commonly reported adverse event for PHENOBARBITAL SODIUM, but still significant enough to appear in the safety profile.
In addition to drug ineffective for unapproved indication, the following adverse reactions have been reported for PHENOBARBITAL SODIUM:
The following drugs have also been linked to drug ineffective for unapproved indication in FDA adverse event reports:
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION has been reported as an adverse event in 17 FDA reports for PHENOBARBITAL SODIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION accounts for approximately 1.8% of all adverse event reports for PHENOBARBITAL SODIUM, making it a notable side effect.
If you experience drug ineffective for unapproved indication while taking PHENOBARBITAL SODIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.